Title
Molecular Diagnostics: For The Clinical Laboratorian,Used
Sold by Ergodebooks, an authorized reseller.
Returns accepted within 30 days | support@ergodebooks.com
Shipping Information
- Free Standard Shipping — United States only
- Processing Time: 1–3 business days
- Estimated Delivery: 3–5 business days after dispatch
- Double-boxed, fully insured & discreetly packaged
- Tracking number sent via email once dispatched
- Orders over $250 require signature upon delivery. Taxes calculated at checkout.
Returns & Refund
Returns accepted within 30 days of delivery.
Damaged or Defective Item
Free return shipping + replacement or full refund
Wrong Item Received
Free return shipping + replacement or full refund
Change of Mind
Return shipping at customer's expense · 25% restocking fee applies
Payment Option
In 1994 I coedited a book, Molecular Pathology: Ap efforts. It should be evident that molecular pathology and proaches to Diagnosing Human Disease in the Clinical diagnostics impact almost every conceivable subspecialty Laboratory, that coined the phrase molecular pathology in laboratory medicine and, particularly in the case of to refer to applications of molecular biology in the tradi pharmacogenomics, have led to the development of new tional areas of laboratory medicine. That compilation of areas of investigation. clinical molecular techniques included 11 chapters and an What is less evident is the burden placed upon the epilogue on New Directions for the Clinical Laboratory. laboratorians directing these efforts. Issues regarding Chapter headings included: automation, neoplasia, heri training, certification, continuing education, and re table diseases, and infectious diseases. bursement (just to name a few) have demanded enormous Three years later, in 1997, Bill Coleman and Greg Tson time and effort from professional organizations and g galis edited Molecular Diagnostics: For the Clinical ernmental agencies. In addition, because conventional Laboratorian, which contained 18 chapters and introduced approaches cannot always be applied to molecular di the new areas of RTPCR and In Situ PCR, and included nostics, unique solutions for quality assurance and quality a section on gene therapy. Now, ten years after the intro control must be developed. These challenges have eng duction of molecular pathology, we are looking at the dered committees, subcommittees, taskforces, and second edition of Bill Coleman and Greg Tsongalis text.
⚠️ WARNING (California Proposition 65):
This product may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
For more information, please visit www.P65Warnings.ca.gov.